Wave Life Sciences, Inc. (WVE)
Wave Life Sciences, Inc. (WVE) from its SEC filings: 2025 revenue $42.7 million (-60% vs the year before), net margin -478%, free cash flow -$188.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $42.7 million |
| Revenue growth | -60% |
| Net income | -$204.4 million |
| Net margin | -478.4% |
| Free cash flow | -$188.2 million |
| Diluted EPS | $-1.21 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -74% |
| Cash | $368.0 million |
| Share count, 1 year | +24% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.